Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT06287411
Overview
This study aimed to prospectively evaluate the utility of fibroblast activation protein inhibitor (FAPI) positron emission tomography (PET)/magnetic resonance (MR) combined with gadoxetate disodium in patients with clinical suspected hepatic malignancies (lesion diameter ≤ 3.0cm), with histopathological findings obtained from biopsy or resected surgical specimens, or follow-up results as reference standards.
Sponsor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase
N/A
Contacts
Xiao Chen, Ph.D (Principal Investigator)
xiaochen229@foxmail.com
+8615922970174
ClinicalTrials.gov
NCT06287411Drug / Compound
Help us improve your experience